PL361397A1 - Pochodne imidazolu jako inhibitory kinazy Raf - Google Patents

Pochodne imidazolu jako inhibitory kinazy Raf

Info

Publication number
PL361397A1
PL361397A1 PL01361397A PL36139701A PL361397A1 PL 361397 A1 PL361397 A1 PL 361397A1 PL 01361397 A PL01361397 A PL 01361397A PL 36139701 A PL36139701 A PL 36139701A PL 361397 A1 PL361397 A1 PL 361397A1
Authority
PL
Poland
Prior art keywords
kinase inhibitors
raf kinase
imidazole derivatives
migraine
pain
Prior art date
Application number
PL01361397A
Other languages
English (en)
Inventor
David Kenneth Dean
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0023197A external-priority patent/GB0023197D0/en
Priority claimed from GB0023193A external-priority patent/GB0023193D0/en
Priority claimed from GB0023196A external-priority patent/GB0023196D0/en
Priority claimed from GB0023208A external-priority patent/GB0023208D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of PL361397A1 publication Critical patent/PL361397A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL01361397A 2000-09-21 2001-09-19 Pochodne imidazolu jako inhibitory kinazy Raf PL361397A1 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0023197A GB0023197D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023193A GB0023193D0 (en) 2000-09-21 2000-09-21 Compounds
GB0023196A GB0023196D0 (en) 2000-09-21 2000-09-21 Compouds
GB0023208A GB0023208D0 (en) 2000-09-21 2000-09-21 Compounds
PCT/GB2001/004195 WO2002024680A1 (en) 2000-09-21 2001-09-19 Imidazole derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
PL361397A1 true PL361397A1 (pl) 2004-10-04

Family

ID=27447885

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01361397A PL361397A1 (pl) 2000-09-21 2001-09-19 Pochodne imidazolu jako inhibitory kinazy Raf

Country Status (21)

Country Link
US (2) US7199137B2 (pl)
EP (1) EP1318992B1 (pl)
JP (1) JP2004509882A (pl)
KR (1) KR20030030027A (pl)
CN (1) CN1471523A (pl)
AT (1) ATE300529T1 (pl)
AU (1) AU2001287901A1 (pl)
BR (1) BR0114023A (pl)
CA (1) CA2423154A1 (pl)
CY (1) CY1105251T1 (pl)
CZ (1) CZ2003793A3 (pl)
DE (1) DE60112312T2 (pl)
DK (1) DK1318992T3 (pl)
ES (1) ES2242767T3 (pl)
HU (1) HUP0301181A2 (pl)
IL (1) IL154949A0 (pl)
MX (1) MXPA03002449A (pl)
NO (1) NO20031270L (pl)
PL (1) PL361397A1 (pl)
PT (1) PT1318992E (pl)
WO (1) WO2002024680A1 (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
ATE266022T1 (de) * 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
ATE365730T1 (de) * 2000-11-20 2007-07-15 Smithkline Beecham Corp Neuartige verbindungen
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121490D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US20040192689A1 (en) * 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003221684A1 (en) * 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
TW200424183A (en) * 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
CN101870691A (zh) 2002-08-19 2010-10-27 劳洛斯治疗公司 2,4,5-三取代的咪唑及其作为抗菌剂的用途
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
US20070099250A1 (en) * 2003-04-14 2007-05-03 Ping Hu Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
US7569593B2 (en) * 2003-10-02 2009-08-04 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
AU2006250809B2 (en) 2005-05-25 2011-05-12 Lorus Therapeutics Inc. 2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
JP2010508855A (ja) * 2006-11-08 2010-03-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用
CA2676422C (en) 2007-02-06 2018-10-16 Lixte Biotechnology Holdings, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CA2692793C (en) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
EA018618B1 (ru) * 2007-10-01 2013-09-30 Ликсте Байотекнолоджи, Инк. Ингибиторы hdac
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
EP2478120B1 (en) 2009-09-17 2015-09-02 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2011085269A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Raf kinase inhibitors
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
EP2739143B1 (en) * 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
KR20160042811A (ko) 2013-03-20 2016-04-20 압토스 바이오사이언시스 인코포레이티드 2-치환 이미다조[4,5-d]페난쓰롤린 유도체 및 암 치료에 있어서의 이의 용도
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
MX2019006694A (es) 2016-12-08 2019-08-21 Lixte Biotechnology Inc Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2022249192A1 (en) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
EP0833664A1 (en) 1995-06-12 1998-04-08 G.D. SEARLE & CO. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
JP2000511558A (ja) 1996-06-21 2000-09-05 アラーガン・セイルズ・インコーポレイテッド レチノイドおよび／またはレチノイド拮抗剤様生物学的活性を有する置換テトラヒドロナフタレンおよびジヒドロナフタレン誘導体
DE69729946T2 (de) 1996-10-15 2005-01-20 G.D. Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
CA2269128C (en) 1996-10-30 2005-01-11 Schering Corporation Piperazino derivatives as neurokinin antagonists
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
CA2310046A1 (en) 1997-11-14 1999-05-27 Sankyo Company Limited Pyridylpyrrole derivatives
AU5247599A (en) 1998-07-30 2000-02-21 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles

Also Published As

Publication number Publication date
EP1318992B1 (en) 2005-07-27
CY1105251T1 (el) 2010-03-03
CN1471523A (zh) 2004-01-28
PT1318992E (pt) 2005-11-30
ATE300529T1 (de) 2005-08-15
CA2423154A1 (en) 2002-03-28
AU2001287901A1 (en) 2002-04-02
IL154949A0 (en) 2003-10-31
BR0114023A (pt) 2004-02-03
DE60112312T2 (de) 2005-12-29
JP2004509882A (ja) 2004-04-02
US20040038964A1 (en) 2004-02-26
HUP0301181A2 (en) 2007-02-28
WO2002024680A1 (en) 2002-03-28
US20070135433A1 (en) 2007-06-14
DE60112312D1 (de) 2005-09-01
CZ2003793A3 (cs) 2004-04-14
KR20030030027A (ko) 2003-04-16
NO20031270D0 (no) 2003-03-19
DK1318992T3 (da) 2005-11-21
EP1318992A1 (en) 2003-06-18
US7199137B2 (en) 2007-04-03
NO20031270L (no) 2003-05-19
ES2242767T3 (es) 2005-11-16
MXPA03002449A (es) 2003-06-19

Similar Documents

Publication Publication Date Title
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
GB0121490D0 (en) Ciompounds
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
ZA200500323B (en) Use of lkb kinase inhibitors for the treatment of pain.
WO2003080582A3 (de) Fredericamycin-derivate
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
IL172942A0 (en) Pyrazoloisoquinoline derivatives as kinase inhibitors
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
WO2003028721A3 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
GB0121494D0 (en) Compounds
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
WO2005021510A3 (en) Benzimidazole c-2 heterocycles as kinase inhibitors
MY148617A (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
UA90254C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors
WO2003004631A3 (en) USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)